全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Congenital Arthrogryposis: An Extension of the 15q11.2 BP1-BP2 Microdeletion Syndrome?

DOI: 10.1155/2014/127258

Full-Text   Cite this paper   Add to My Lib

Abstract:

The proximal 15q11–q13 region contains 5 breakpoints (BP1–BP5). The BP1-BP2 region spans approximately 500?kb and contains four evolutionarily conserved genes. The genes in this region are known to play a role in central nervous system development and/or function. Microdeletions within the 15q11.2 BP1-BP2 region have been reported in patients with neurological dysfunction, developmental delays, behavioral problems, and dysmorphic features. We report two unrelated subjects with the 15q11.2 BP1-BP2 microdeletion and presenting with congenital arthrogryposis, a feature which has not been previously reported as part of this newly recognized microdeletion syndrome. While arthrogryposis seen in these two subjects may be coincidental, we propose that congenital arthrogryposis may result from neurological dysfunction and involvement of the microdeletion of the 15q11.2 BP1-BP2 region, further expanding the phenotype of this microdeletion syndrome. We encourage others to report patients with this chromosome microdeletion and neurological findings to further characterize the clinical phenotype. 1. Introduction The proximal 15q11–q13 region contains 5 breakpoints (BP1–BP5) located at low copy repeats implicated in causing chromosomal anomalies, primarily deletions, and duplications due to nonallelic homologous recombination [1, 2]. The most widely recognized deletion in this region is associated with two syndromes, Prader-Willi (PWS) and Angelman (AS), depending on the parent of origin and errors in genomic imprinting. The classical 15q11–q13 deletion seen in PWS or AS is of two types, a longer type I deletion involving BP1 and BP3 or the shorter type II deletion involving BP2 and BP3. Those with the longer type I deletion, in either PWS or AS, are reported with a more severe phenotype than those with the type II deletion [3–5]. The BP1-BP2 region spans approximately 500?kb and contains four evolutionarily conserved genes that are not imprinted: NIPA1, NIPA2, CYFIP1, and TUBGCP5 [6]. These genes are implicated in playing a role in central nervous system development and function; for example, mutations of NIPA1 are associated with spastic paraplegia [7, 8]. The related NIPA2 gene is widely expressed in the central nervous system and encodes for a magnesium transporter [9]. The CYFIP1 gene encodes a protein that interacts with FMRP, the protein product of the FMR1 gene responsible for fragile X syndrome [10]. This syndrome is the most common cause of familial intellectual disability and primarily affects males [11]. The fourth gene, TUBGCP5, is a member of the

References

[1]  D. C. Bittel and M. G. Butler, “Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology,” Expert Reviews in Molecular Medicine, vol. 7, no. 14, pp. 1–20, 2005.
[2]  M. G. Butler, “Prader-willi syndrome: obesity due to genomic imprinting,” Current Genomics, vol. 12, no. 3, pp. 204–215, 2011.
[3]  M. G. Butler, D. C. Bittel, N. Kibiryeva, Z. Talebizadeh, and T. Thompson, “Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy,” Pediatrics, vol. 113, no. 3, pp. 565–573, 2004.
[4]  T. Sahoo, C. A. Bacino, J. R. German et al., “Identification of novel deletions of 15q11q13 in Angelman syndrome by array-CGH: molecular characterization and genotype-phenotype correlations,” European Journal of Human Genetics, vol. 15, no. 9, pp. 943–949, 2007.
[5]  C. A. Williams, D. J. Driscoll, and A. I. Dagli, “Clinical and genetic aspects of Angelman syndrome,” Genetics in Medicine, vol. 12, no. 7, pp. 385–395, 2010.
[6]  J.-H. Chai, D. P. Locke, J. M. Greally et al., “Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons,” American Journal of Human Genetics, vol. 73, no. 4, pp. 898–925, 2003.
[7]  A. Goytain, R. M. Hines, A. El-Husseini, and G. A. Quamme, “NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg2+ transporter,” Journal of Biological Chemistry, vol. 282, no. 11, pp. 8060–8068, 2007.
[8]  S. Rainier, J.-H. Chai, D. Tokarz, R. D. Nicholls, and J. K. Fink, “NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6),” American Journal of Human Genetics, vol. 73, no. 4, pp. 967–971, 2003.
[9]  A. Goytain, R. M. Hines, and G. A. Quamme, “Functional characterization of NIPA2, a selective Mg2+ transporter,” American Journal of Physiology, vol. 295, no. 4, pp. C944–C953, 2008.
[10]  I. Napoli, V. Mercaldo, P. P. Boyl et al., “The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP,” Cell, vol. 134, no. 6, pp. 1042–1054, 2008.
[11]  D. C. Crawford, J. M. Acu?a, and S. L. Sherman, “FMR1 and the fragile X syndrome: human genome epidemiology review,” Genetics in Medicine, vol. 3, no. 5, pp. 359–371, 2001.
[12]  D. C. Bittel, N. Kibiryeva, and M. G. Butler, “Expression of 4 genes between chromosome 15 breakpoints 1 and 2 and behavioral outcomes in Prader-Willi syndrome,” Pediatrics, vol. 118, no. 4, pp. e1276–e1283, 2006.
[13]  S. K. Murthy, A. O. H. Nygren, H. M. El Shakankiry et al., “Detection of a novel familial deletion of four genes between BP1 and BP2 of the Prader-Willi/Angelman syndrome critical region by oligo-array CGH in a child with neurological disorder and speech impairment,” Cytogenetic and Genome Research, vol. 116, no. 1-2, pp. 135–140, 2007.
[14]  H. Stefansson, D. Rujescu, S. Cichon et al., “Large recurrent microdeletions associated with schizophrenia,” Nature, vol. 455, no. 7210, pp. 232–236, 2008.
[15]  G. Kirov, D. Grozeva, N. Norton et al., “Support for the involvement of large copy number variants in the pathogenesis of schizophrenia,” Human Molecular Genetics, vol. 18, no. 8, pp. 1497–1503, 2009.
[16]  M. Doornbos, B. Sikkema-Raddatz, C. A. L. Ruijvenkamp et al., “Nine patients with a microdeletion 15q11.2 between breakpoints 1 and 2 of the Prader-Willi critical region, possibly associated with behavioural disturbances,” European Journal of Medical Genetics, vol. 52, no. 2-3, pp. 108–115, 2009.
[17]  C. G. F. de Kovel, H. Trucks, I. Helbig et al., “Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies,” Brain, vol. 133, no. 1, pp. 23–32, 2010.
[18]  R. D. Burnside, R. Pasion, F. M. Mikhail et al., “Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: a susceptibility region for neurological dysfunction including developmental and language delay,” Human Genetics, vol. 130, no. 4, pp. 517–528, 2011.
[19]  D. Wong, S. M. Johnson, D. Young, L. Iwamoto, S. Sood, and T. P. Slavin, “Expanding the BP1-BP2 15q11.2 microdeletion phenotype: tracheoesophageal fistula and congenital cataracts,” Case Reports in Genetics, vol. 2013, Article ID 801094, 3 pages, 2013.
[20]  M. Bamshad, A. E. Van Heest, and D. Pleasure, “Arthrogryposis: a review and update,” Journal of Bone and Joint Surgery. American, vol. 91, no. 4, pp. 40–46, 2009.
[21]  J. G. Hall, “Genetic aspects of arthrogryposis,” Clinical Orthopaedics and Related Research, vol. 194, pp. 44–53, 1985.
[22]  N. Darin, E. Kimber, A.-K. Kroksmark, and M. Tulinius, “Multiple congenital contractures: birth prevalence, etiology, and outcome,” Journal of Pediatrics, vol. 140, no. 1, pp. 61–67, 2002.

Full-Text

Contact Us

[email protected]

QQ:3279437679

WhatsApp +8615387084133